Pacira BioSciences, Company Insiders

PCRX Stock  USD 24.14  0.32  1.34%   
Slightly above 80 percent of Pacira BioSciences,'s insiders are selling. The analysis of insiders' sentiment of trading Pacira BioSciences, stock suggests that a fairly large number of insiders are terrified at this time. Pacira BioSciences, employs about 788 people. The company is managed by 18 executives with a total tenure of roughly 38 years, averaging almost 2.0 years of service per executive, having 43.78 employees per reported executive.
David Stack  Chairman
Chairman and CEO

Insider Sentiment 20

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-01-06Jonathan SloninDisposed 879 @ 18.4View
2024-12-13Daryl GauglerDisposed 500 @ 19.76View
2024-09-13Daryl GauglerDisposed 500 @ 12.86View
2024-08-16Marcelo BigalAcquired 1512 @ 13.25View
2024-08-12Mark FroimsonAcquired 1400 @ 11.58View
2024-08-02Jonathan SloninDisposed 945 @ 20.05View
2024-07-02Jonathan SloninDisposed 2836 @ 28.25View
2024-06-13Paul J HastingsDisposed 880 @ 28.38View
2024-06-12Lauren RikerDisposed 3970 @ 28.72View
2024-06-11Jonathan SloninDisposed 5012 @ 28.57View
Monitoring Pacira BioSciences,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira BioSciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Pacira BioSciences,'s Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pacira BioSciences,'s future performance. Based on our forecasts, it is anticipated that Pacira will maintain a workforce of slightly above 790 employees by April 2025.
 
Credit Downgrade
 
Yuan Drop
 
Covid

Pacira BioSciences, Management Team Effectiveness

The company has return on total asset (ROA) of 0.039 % which means that it generated a profit of $0.039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1208) %, meaning that it created substantial loss on money invested by shareholders. Pacira BioSciences,'s management efficiency ratios could be used to measure how well Pacira BioSciences, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.09 in 2025. Return On Capital Employed is likely to drop to -0.06 in 2025. At this time, Pacira BioSciences,'s Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 241.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 414.1 M in 2025.
Net Income Applicable To Common Shares is likely to rise to about 19.2 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 36.8 M in 2025.

Pacira BioSciences, Workforce Comparison

Pacira BioSciences, is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 34,763. Pacira BioSciences, holds roughly 788 in number of employees claiming about 2.27% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16.

Pacira BioSciences, Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacira BioSciences, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacira BioSciences,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pacira BioSciences, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.5
6
4
 706,900 
 10,784 
2024-12-01
3.0
3
1
 275,244 
 500.00 
2024-09-01
1.2
6
5
 17,576 
 5,500 
2024-06-01
2.5
25
10
 353,759 
 30,516 
2024-03-01
1.5
6
4
 874,432 
 119,482 
2023-12-01
0.6667
4
6
 123,868 
 111,937 
2023-06-01
0.7436
29
39
 583,200 
 126,821 
2022-06-01
0.9167
44
48
 827,110 
 334,126 
2022-03-01
0.6512
28
43
 157,922 
 248,193 
2021-12-01
0.1765
3
17
 32,500 
 158,075 
2021-09-01
0.75
6
8
 32,500 
 57,058 
2021-06-01
1.3448
39
29
 433,909 
 175,751 
2021-03-01
0.2222
6
27
 46,520 
 387,484 
2020-12-01
0.25
5
20
 100,000 
 445,000 
2020-09-01
0.3846
15
39
 164,404 
 599,326 
2020-06-01
1.5556
42
27
 1,160,846 
 186,637 
2020-03-01
0.8
12
15
 92,828 
 109,200 
2019-12-01
0.5769
15
26
 97,448 
 209,674 
2019-09-01
0.5
5
10
 246,768 
 72,180 
2019-06-01
2.0
36
18
 556,007 
 87,312 
2018-12-01
0.4211
8
19
 66,500 
 223,738 
2018-09-01
0.2
5
25
 36,091 
 272,866 
2018-06-01
1.9333
29
15
 489,700 
 114,466 
2018-03-01
0.5
2
4
 88,885 
 57,770 
2017-12-01
0.4167
5
12
 68,770 
 196,730 
2017-09-01
0.6
3
5
 43,985 
 77,275 
2017-06-01
1.56
39
25
 509,182 
 209,144 
2017-03-01
0.4286
3
7
 35,000 
 70,000 
2016-12-01
1.8333
11
6
 233,000 
 100,000 
2016-09-01
0.6
3
5
 40,000 
 80,000 
2016-06-01
3.0
30
10
 412,491 
 54,574 
2016-03-01
1.0
7
7
 21,800 
 36,000 
2015-12-01
0.5
3
6
 58,000 
 36,000 
2015-09-01
1.25
5
4
 138,000 
 36,000 
2015-06-01
5.5
22
4
 109,250 
 55,000 
2015-03-01
0.4
8
20
 64,849 
 119,349 
2014-12-01
0.3333
7
21
 37,225 
 138,041 
2014-09-01
0.4
14
35
 583,500 
 894,007 
2014-06-01
0.625
20
32
 467,000 
 501,900 
2014-03-01
1.0
4
4
 16,725 
 26,887 
2013-12-01
0.6
9
15
 97,997 
 195,000 
2013-09-01
0.3636
12
33
 216,987 
 729,193 
2013-06-01
0.375
24
64
 263,853 
 1,733,974 
2013-03-01
0.4167
25
60
 630,143 
 8,742,900 
2012-03-01
0.4063
13
32
 8,237,883 
 7,122,644 
2011-12-01
3.5
7
2
 2,017,690 
 97,441 
2011-06-01
3.0
6
2
 71,384 
 0.00 
2011-03-01
1.64
82
50
 27,986,922 
 21,650,746 

Pacira BioSciences, Notable Stakeholders

A Pacira BioSciences, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pacira BioSciences, often face trade-offs trying to please all of them. Pacira BioSciences,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pacira BioSciences,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Frank LeeCEO DirectorProfile
David StackChairman and CEOProfile
Richard KahrVice ResourcesProfile
Daryl GauglerChief OfficerProfile
Charles LaranjeiraChief Technical OfficerProfile
Christopher YoungChief OfficerProfile
Shawn CrossChief OfficerProfile
JD EsqChief SecretaryProfile
DO EllisChief OfficerProfile
III CPAChief OfficerProfile
Max ReinhardtPres WorldProfile
Dennis McLoughlinChief Commercial OfficerProfile
Kristen JDChief SecretaryProfile
Roy MDChief OfficerProfile
Susan MescoIR Contact OfficerProfile
Jonathan MDChief OfficerProfile
Lauren RikerPrincipal FinanceProfile
Esq IIIChief OfficerProfile

About Pacira BioSciences, Management Performance

The success or failure of an entity such as Pacira BioSciences, often depends on how effective the management is. Pacira BioSciences, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pacira management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pacira management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.09)(0.09)
Return On Capital Employed(0.06)(0.06)
Return On Assets(0.06)(0.07)
Return On Equity(0.13)(0.13)
Please note, the imprecision that can be found in Pacira BioSciences,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pacira BioSciences,. Check Pacira BioSciences,'s Beneish M Score to see the likelihood of Pacira BioSciences,'s management manipulating its earnings.

Pacira BioSciences, Workforce Analysis

Traditionally, organizations such as Pacira BioSciences, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pacira BioSciences, within its industry.

Pacira BioSciences, Manpower Efficiency

Return on Pacira BioSciences, Manpower

Revenue Per Employee889.6K
Revenue Per Executive38.9M
Net Loss Per Employee126.3K
Net Loss Per Executive5.5M
Working Capital Per Employee552.3K
Working Capital Per Executive24.2M

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.